Genome-wide association studies (GWAS) in ethnic/racial minority populations can help to fine-map previously identified risk regions or discover new risk loci because of the genetic diversity in these populations. We conducted a GWAS of colorectal cancer (CRC) in 6,597 African Americans (1,894 cases and 4,703 controls) (Stage 1) and followed up the most promising markers in a replication set of 2,041 participants of African descent (891 cases and 1,150 controls) (Stage 2). We identified a novel variant, rs56848936 in the gene SYMPK at 19q13.3, associated with colon cancer risk (odds ratio 0.61 for the risk allele G, p 5 2.4 3 10
Introduction
Globally, colorectal cancer (CRC) is the third and second most common cancer in men and women, respectively, (www.who.int; International Agency for Research on Cancer GLOBOCAN). Genetic susceptibility plays an important role in the etiology of CRC through rare, highly deleterious germline mutations (e.g., in APC, MLH1, and MSH2), as well as through common, low-penetrance variants. Over 50 common variants have been identified in genome-wide association studies (GWAS) to date. 1 However, most GWAS of CRC have been conducted in Europeans and East Asians, and only limited data are available for other populations. Studies in populations of African ancestry are particularly important in that: (i) shorter linkage disequilibrium (LD) blocks in this population 2 facilitate pinpointing the best risk-defining variants, that is, for fine-mapping, and (ii) the greater genetic diversity in African-descent populations may lead to discovery of additional susceptibility variants.
As part of our GWAS, we previously reported finemapping results among 6,597 African Americans (1,894 cases and 4,703 controls) 3 for 21 published GWAS-identified CRC risk regions. To our knowledge, this was the first GWAS of CRC conducted exclusively in African Americans. Here we followed up all promising markers from this GWAS in an additional set of 2,041 African American participants (891 cases and 1,150 controls). The Hispanics is another admixed population useful for fine-mapping with shorter LD structure compared to Europeans. 4 We therefore tried to replicate our most suggestive findings in this population.
Materials and Methods
Participants, genotypes, and quality control (QC) 
Statistical analysis
Principal components (PCs) were calculated based on 22,000 genome-wide unrelated markers in Stage 1 and on 119 AIMs in Stage 2. Pair-wise PC plots suggested that the first two PCs were most informative for global ancestry and the distribution of the first PCs were similar in cases and controls in both stages (Fig.  S2 ). In both stages, logistic regression of CRC on allelic dosage with adjustment for age at blood draw, sex and the first four PCs was performed to obtain odds ratio (OR) estimates and 95% confidence interval (CI) per increase in allele count. In Stage 1, age was categorized as <55 years, 5-year intervals from 55 to 80, and 80 years. In Stage 2, analyses were additionally adjusted for study; we also checked that there was no strong betweenstudy heterogeneity in Stage 2 with a likelihood-ratio test. Analysis by anatomical sub-site was performed for colon, rectal, left colon and right colon tumors in both stages.
To combine results from the two stages and for further meta-analysis with the Hispanic studies, a fixed-effect model with inverse variance weighting was implemented in MET-AL. 8 Heterogeneity measure I 2 was calculated, and Cochran's Q statistic was used to test for heterogeneity. 9 
Replication in Hispanics/Latinos
The Hispanic Colorectal Cancer Study is a population-based study of individuals self-identified as Hispanic/Latino with a diagnosis of CRC. Details about these studies were previously published 10 
Results
Characteristics of study participants are shown in Table 1 . Among participants in Stage 1 (GWAS), cases were on average older than controls (mean age 68 and 62 years, respectively) and the proportion of females was higher in cases Overall, for colorectal cancer, when all participants in both stages were included in the analyses, no p-value of association passed the Bonferroni-corrected threshold 5 3 10 28 for GWAS. Among the 27 GWAS-identified CRC risk variants, nine p-values for association in the combined analysis were <0.05 (Table S1 ). Twenty-three risk estimates were of the same direction as those originally reported (85%), and the four with opposite direction of associations were estimated with high uncertainty (p-values > 0.35). Lack of replication could be due to our relatively low power for some of the reported risk estimates (a priori power <80% for 11 SNPs) (Table S2 ), or to the fact that the biologically relevant variants are correlated with the index variants in the original GWAS population, but not so in African Americans. We note that the results in Stage 1 alone for these 27 SNPs were previously reported. 3 In our previous fine-mapping analysis of 27 GWAS regions using the Stage 1 data, rs7252505 at the 19q13.1 locus was more strongly associated with CRC than the published index hit rs10411210 (p 5 1.8 3 10 24 and 0.11, respectively). 3 We replicated this association in Stage 2 with p-value of 9.9 3 10 25 for rs7252505, compared to the p-value of 0.78 for rs10411210 (Table 2 ). When we combined the results from African Americans in Stage 2 with those from the Hispanic GWAS, the common A allele was associated with a reduction in CRC risk at the p-value threshold 5 3 10
28
(OR 5 0.84, 95% CI: 0.79-0.89, p 5 3.7 3 10 28 ) ( Table 2 ). In 1KGP, rs7252505 and rs10411210 are correlated in EUR (r 2 In the anatomical subsite analysis, an association was found between rs56848936 (G/A) in the 19q13.3 region and colon cancer risk (Table 3) ). Genome-wide association statistics for colon cancer in Stage 1 also did not show deviation from the expected (Fig. S3) , indicating the result in Stage 1 was not due to bias caused by population stratification. The risk allele 
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was not observed in the 1KGP EUR or East Asian populations and was rare in Amerindians (frequency <0.01). We therefore could not replicate this finding in other studies, including in the Hispanic GWAS. Associations between rs56848936 and rectal cancer (p 5 0.23) and overall CRC (p 5 9.0 3 10
27
) are shown in Table S3 . All associations with p-values <0.05 in stage 2 are shown in Table S4 .
Discussion
It is important to assess the strength and robustness of GWAS-identified association signals in diverse racial/ethnic populations to gain insight into the pathogenesis of population-specific variants. By genotyping a second independent sets of studies in African Americans, we confirmed the association between CRC and rs7252505, a candidate risk SNP identified in our previous fine-mapping study of the 19q13 locus. When we combined the results from both stages and a Hispanic CRC GWAS, the p-value for the association was 3.7 3 10
28
. Furthermore, we identified a novel risk variant, rs56848936, for colon cancer in African Americans.
We found that, in the known 19q13 risk locus, rs7252505 was more strongly associated with CRC in African Americans than the original index SNP, rs10411210, identified in a European GWAS.
11 Rs10411210 is intronic to RHPN2 (rhophilin, Rho GTPase binding protein 2), and rs7252505 is intronic to the neighboring gene GPATCH1 (G-patch domain containing 1). RHPN2 is a master regulator of actin cytoskeleton rearrangement with a role in various actin-modulating protein targets.
12 Rs10411210 and the SNPs in LD with it have been studied further since the original report. rs10411210 is located in a region with DNase I hypersensitivity in many cell lines and with strong evidence of promoter histone marks (H3K9ac, H3K4me3) in colon and rectal mucosa cells, according to the ENCODE/Roadmap epigenomic data summarized by HaploReg 4.1.
13,14 A non-synonymous SNP in RHPN2, rs28626308 (R70Q), which is weakly correlated with rs10411210 in Europeans (r 2 5 0.21), was suggested as a functional candidate in this region.
15 rs28626308, and the only SNP in high LD with it in AFR in 1KGP (r 2 > 0.8), rs28840750, were not genotyped and not imputed with high accuracy (R 2 > 0.8) in our African American data, perhaps owing to their relatively lower frequencies in this population (minor allele frequency 0.06 in AFR in 1KGP). The functional basis for the rs7252505 association signal observed here is also not clear. Although GPATCH1 is expressed in the colon, little is known about its function other than the fact that it contains a G-patch domain, a domain typically associated with RNA processing. rs7252505 itself maps to putative regulatory elements marked by histone modification in a few cell types but not in colon or rectal cells. 13 No SNP in the 1KGP AFR data is in high LD (r 2 0.8) with rs7252505. rs56848936 (chr19, 46321507 bp), the SNP in the 19q13.3 region identified as being associated with colon cancer in the present study is intronic to the SYMPK genes encoding symplekin. This nuclear protein is thought to participate in the regulation of polyadenylation 16 and gene expression and in 3 0 -end maturation of histone mRNAs, which do not undergo polyadenylation.
17 rs56848936 maps to DNase hypersensitive regions in stem cells and muscle cells and to promoter regions in stem cells (ES, ES-derived and iPS cells) with strong histone modification marks (H3K4me3 and H3K9ac), although evidence for such marks is weak in colon or rectal cancer cell lines. 13, 14 Among the SNPs (r 2 0.8) in high LD with rs56848936 in AFR, rs142542461 (chr19, 46366539 bp, r 2 5 0.82 with rs56848936) in the 5 0 -UTR region of SYMPK is a potential functional variant. It is in the promoter region marked by DNase sensitivity and histone marks (H3K4me3) in almost all cell types, including colon and rectal tumors, as described in the Roadmap Epigenomics project.
14 Interestingly, symplekin, which is found in tight junctions of the epithelial cells, has been shown to enhance cell proliferation and inhibit cell differentiation in colorectal cancer cell lines. [18] [19] [20] Nonetheless, we are not aware of any molecular features in the region including rs56848936 that may explain the specific association with colon cancer and not rectal cancer. rs142542461 was not available in our African American data. Similar to rs56848936, rs142542461 is monomorphic in the EUR and East Asian data and has a minor allele frequency of 0.01 in Amerindians in 1KGP.
In summary, the present study confirmed that rs7252505 may be a better index risk variant in African Americans, further characterizing the 19q13 CRC susceptibility locus. The study also identified a novel risk SNP (rs56848936) in the 19q13.3 region for colon cancer. It is possible that our results are due to chance and further work is needed to validate and better characterize these findings. If confirmed, the association between rs56848936 and colon cancer observed in African Americans would be population-specific since this variation is not observed in Europeans or East Asians. 
